InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.90
(
1.86%
)
US TECH 100
19,402.20
(
2.89%
)
Dow Jones
42,067.33
(
1.36%
)
Brent Oil
74.43
(
2.83%
)
Bitcoin
63,479.70
(
2.93%
)
Post# of 964
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

midastouch017

Send PM Follow Ignore
Followers 144
Posts 27707
Boards Moderated 3
Alias Born 02/07/2004

midastouch017

Re: Spideyboy post# 80

Monday, 07/27/2020 6:03:57 AM

Monday, July 27, 2020 6:03:57 AM

Post# of 964
One of GMDA pipeline products is GDA-201
[Non-Hodgkin Lymphoma.]

I stumbeled upon this:

https://www.businesswire.com/news/home/20200724005428/en/

U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma
-- 87 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus --

-- Kite Becomes First Company with Multiple Approved CAR T Therapies -

In your opinion is GMDA too late with GDA indication?

TIA
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up